LOX-IN-3

液氧-IN-3

LOX-IN-3

L655479-1ml

1ml

10mM in DMSO

避光,-80℃储存

超低温冰袋运输

LOX-IN-3 is an orally active lysyl oxidase (LOX) inhibitor. LOX-IN-3 can be used for fibrosis, cancer and angiogenesis research In Vitro LOX-IN-3 dihydrochloride monohydrate (Compound 33) inhibits the bovine LOX and human LOXL2 activities with IC 50 values of In Vivo LOX-IN-3 dihydrochloride monohydrate (Compound 33) (30 mg/kg; orally; once) inhibits lysyl oxidase activity in rats . LOX-IN-3 dihydrochloride monohydrate (10 mg/kg; orally; daily for 14 days) reduces kidney fibrosis in unilateral ureteric obstruction (UUO) mice model . LOX-IN-3 dihydrochloride monohydrate (15 mg/kg; orally; daily for 21 days) reduces lung fibrosis in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats Dosage: 30 mg/kg Administration: Oral administration, single dose Result: Completely abolished lysyl oxidase activity. Plasma concentrations of tested compound are far below the IC 50 after 8 hours, the half-life of recovery is between 2-3 days (ear) and 24 hours (aorta). Animal Model: Unilateral ureteric obstruction (UUO) model of acute kidney fibrosis in mice Dosage: 10 mg/kg Administration: Oral gavage, daily for 14 days Result: Increased kidney weight and thickness and reduced the area of fibrosis. Animal Model: C57Bl/6 mice, Bleomycin-induced lung fibrosis model Dosage: 15 mg/kg Administration: Oral gavage, daily for 21 days Result: Significantly reduced the Ashcroft score and the lung weight. IC50& Target:IC 50 :

LOX-IN-3 是一种口服活性赖氨酰氧化酶（LOX）抑制剂。LOX-IN-3 可用于纤维化、癌症和血管生成研究。

2409963-83-1(DMSO)

C13H13FN2O2S

280.32 g/mol

C1=CC2=C(C(=C1)S(=O)(=O)CC(=CCN)F)N=CC=C2